Clinical Trial: NCT05120570
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Masonic Cancer Center, University of Minnesota |
| Information Provided By: | Masonic Cancer Center, University of Minnesota |
| Last Update Posted: | 2025-12-22 |
Study Overview
Brief Summary
This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).
Official Title
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Conditions
Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Lymphoma
Intervention / Treatment
- Drug: VIC- 1911
Other Study ID Numbers
- 2021LS006
- MT2021-01
Start Date (Actual)
2022-03-17
Primary Completion Date (Actual)
2024-09-19
Study Completion Date (Actual)
2025-06-30
Enrollment (Actual)
16
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Masonic Cancer Center, University of Minnesota |
| Information Provided By: | Masonic Cancer Center, University of Minnesota |
| Last Update Posted: | 2025-12-22 |
Study Overview
Brief Summary
This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).
Official Title
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Conditions
Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Lymphoma
Intervention / Treatment
- Drug: VIC- 1911
Other Study ID Numbers
- 2021LS006
- MT2021-01
Start Date (Actual)
2022-03-17
Primary Completion Date (Actual)
2024-09-19
Study Completion Date (Actual)
2025-06-30
Enrollment (Actual)
16
Study Type
Interventional
Phase
Phase 1, Phase 2